The Ongoing Impact of MFN Pricing
Alice Valdur Curan discusses how the industry continues to strategize around this complicated order.
17m Mar 04
17m
Pharmaceutical Executive Daily: Novo Nordisk Commits $506 Million to Ireland Manufacturing Site
In today’s Pharmaceutical Executive Daily, industry leaders examine how to measure AI’s return on investment across the life sciences value chain, Novo Nordisk commits $506 million to expand its Ireland manufacturing facility, and Bavarian Nordic CEO Paul Chaplin announces plans to step down.
2m Mar 03
2m
Pharmaceutical Executive Daily: FDA Approves Palynziq and Sogroya
In today’s Pharmaceutical Executive Daily, the FDA approves an expanded indication for Palynziq in patients aged 12 and older, Sogroya becomes the first and only weekly long-acting growth hormone approved for pediatric use, and experts examine how real-world data strengthens natural history disease research.
2m Mar 02
2m
Pharmaceutical Executive Daily: FDA Approves Hernexeos
In today’s Pharmaceutical Executive Daily, the FDA approves Hernexeos under a national priority voucher program, industry leaders explore the expansion of direct-to-consumer HIV prevention strategies, and Dupixent gains FDA approval for allergic fungal rhinosinusitis.
2m Feb 27
2m
Pharmaceutical Executive Daily: Alkermes' CEO Succession Plan
In today’s Pharmaceutical Executive Daily, Alkermes outlines its CEO succession plan following Richard Pops’ retirement announcement, leadership changes continue at Sarepta Therapeutics and Rivus Pharmaceuticals, and Boehringer Ingelheim secures an exclusive license for a preclinical small-molecule program.
2m Feb 26
2m
The Ron Lanton Report: Is Healthcare Consolidation Reaching Its Limits?
The episode will explore structural implications for supply chains, distribution models, and international strategy, not a political discussion, but a forward-looking planning lens.
10m Feb 26
10m
Pharmaceutical Executive Daily: FDA Approves Braftovi
In today’s Pharmaceutical Executive Daily, the FDA approves Braftovi for mutant metastatic colorectal cancer, Novo Nordisk and GSK announce major deal activity in a mergers and acquisitions roundup, and UK regulators confiscate thousands of doses of illegal weight-loss medicines.
2m Feb 25
2m
Pharmaceutical Executive Daily: Novo Nordisk Announces Price Reductions for GLP-1 Products
In today’s Pharmaceutical Executive Daily, AbbVie invests $380 million to expand API manufacturing capacity while Bora Pharmaceuticals and GSK enter a five-year manufacturing agreement, Novo Nordisk announces significant price reductions for its leading GLP-1 therapies, and Astellas enters a billion-dollar global collaboration with Vir Biotechnology to advance PSMA-targeting cancer treatments.
2m Feb 24
2m
Pharmaceutical Executive Daily: BioNTech Files Patent iInfringement Lawsuit Against Moderna
In today’s Pharmaceutical Executive Daily, BioNTech files a patent infringement lawsuit against Moderna, the Supreme Court rules against a large number of Trump-era tariffs, and the FDA approves a Calquence–venetoclax combination for certain blood cancers.
2m Feb 20
2m
Pharmaceutical Executive Daily: FDA Plans to Remove Two Study Requirement for New Drug Approvals
In today’s Pharmaceutical Executive Daily, the FDA reportedly removes its two-study requirement for new drug approvals, Hims & Hers enters a $1 billion agreement to acquire Eucalyptus, and experts examine how FDA can help ease early-stage clinical trial bottlenecks.
2m Feb 19
2m
Pharmaceutical Executive Daily: FDA Initiates Review of Moderna’s Seasonal Influenza Vaccine
In today’s Pharmaceutical Executive Daily, the FDA begins reviewing Moderna’s seasonal flu vaccine under a revised regulatory approach, Eli Lilly signs a $100 million licensing agreement with CSL for an anti- IL-6 monoclonal antibody., and Southern Florida emerges as a growing biotech hub.
2m Feb 18
2m
Pharmaceutical Executive Daily: FDA Approves New Dosing Schedule for Rybrevant Faspro
In today’s Pharmaceutical Executive Daily, the FDA approves a monthly dosing schedule for Rybrevant Faspro, HHS Secretary Robert F. Kennedy Jr. revises the agency’s leadership team, and industry expert Sandy Tammisetty discusses what it takes to deliver actual value in today’s pharmaceutical landscape.
2m Feb 17
2m
Pharmaceutical Executive Daily: Disc Medicine Receives CRL from FDA for Bitopertin
In today’s Pharmaceutical Executive Daily, the FDA issues a Complete Response Letter for Disc Medicine’s bitopertin in EPP, Edwards Lifesciences lifts its anti-copycat policy, and industry leaders examine how to scale global medical digital transformation while ensuring local fit.
2m Feb 16
2m
Pharmaceutical Executive Daily: Eli Lilly's $1.5 Billion Stockpile of Orforglipron
In today’s Pharmaceutical Executive Daily, Eli Lilly builds a $1.5 billion stockpile of Orforglipron ahead of an FDA decision, PTC Therapeutics withdraws and plans to resubmit its Translarna NDA, and a former AstraZeneca executive is charged with multiple offenses in China.
1m Feb 13
1m
Pharmaceutical Executive Daily: FDA Issues Refusal-to-File Letter to Moderna
In today’s Pharmaceutical Executive Daily, the FDA issues a refusal-to-file letter to Moderna for its seasonal influenza vaccine as the company secures a long-term agreement in Mexico, industry leaders assess China’s evolving role in global pharma strategy, and the FDA makes a decision on Keytruda in platinum-resistant ovarian cancer.
2m Feb 11
2m
Pharmaceutical Executive Daily: Specialized Wealth Management for BioPharmaceutical Sales
In today’s Pharmaceutical Executive Daily, frontline biopharma sales professionals are increasingly turning to specialized wealth management advisory services, QuantX Biosciences and Pandorum Technologies close Series B financing rounds, and Iambi enters a $1 billion collaboration with Takeda to advance small-molecule programs.
2m Feb 10
2m
Bets and Balances: Riding the Risk-and-Innovation Pendulum in Biotech
In a podcast conversation with Pharm Exec, Ken Banta, founder and CEO of The Vanguard Network, and Andrew Hall, CEO of Consano Bio, discuss what effective leadership looks like in today’s volatile capital and regulatory climates for emerging biotechs. Part 1 of the conversation explores why Banta and Hall believe CEOs of these companies must act as stabilizers and translators—balancing risk wit...
18m Feb 10
18m
Pharmaceutical Executive Daily: Hims & Hers Removes Access to New Compounded Semaglutide Pill
In today’s Pharmaceutical Executive Daily, Hims & Hers withdraws access to its compounded semaglutide pill following a controversy filled launch, next-generation trial designs increasingly integrate real-world data, and Eli Lilly enters an $8 billion strategic collaboration involving Innovent and Orna Therapeutics.
2m Feb 09
2m
Pharmaceutical Executive Daily: The Launch of TrumpRx
In today’s Pharmaceutical Executive Daily, TrumpRx officially launches, the FDA moves against mass marketing of illegal copycat drugs, and AI emerges as a force multiplier for small and mid-size biotech companies
2m Feb 06
2m
Pharmaceutical Executive Daily: FDA Approves First and Only Oral Film Treatment for Erectile Dysfunction
In today’s Pharmaceutical Executive Daily, FDA approves Vybrique for erectile dysfunction, experts argue Phase III clinical protocols should be treated as product launch blueprints, and Veradermics completes an upsized $256 million IPO.
2m Feb 05
2m
Pharmaceutical Executive Daily: Susan G. Komen Releases Breast Cancer Outlook for 2026
In today’s Pharmaceutical Executive Daily, Susan G. Komen releases its 2026 breast cancer progress outlook, industry leaders explore how pharma can tap into emerging talent hubs, and Novartis’ Q4 results highlight mounting pressure from its upcoming patent cliff.
2m Feb 04
2m
Pharmaceutical Executive Daily: SanegeneBio's $1.5 Billion License Agreement with Genentech
In today’s Pharmaceutical Executive Daily, a new a is expected to evolve in 2026, the FDA rejects AstraZeneca’s application for a subcutaneous indication of Saphnelo, and SanegeneBio enters a $1 billion global licensing agreement with Genentech focused on RNAi development.
2m Feb 03
2m
Pharmaceutical Executive Daily: FDA Reveals PreCheck Pilot Program
In today’s Pharmaceutical Executive Daily, the FDA introduces a PreCheck pilot program aimed at strengthening domestic manufacturing oversight, an ACIP member alleges FDA leadership halted a decision related to COVID-19 vaccines, and Eli Lilly announces plans for a $3 billion manufacturing facility in Pennsylvania.
2m Feb 02
2m
Pharmaceutical Executive Daily: Public Citizen Sues The Trump Administration Over Undisclosed Drug Price Agreements
In today’s Pharmaceutical Executive Daily, Public Citizen files suit over undisclosed drug pricing agreements involving Pfizer and Eli Lilly, HHS releases new guidance aimed at lowering prescription drug costs through direct-to-consumer programs, and AstraZeneca enters a multibillion-dollar collaboration with CSPC Pharmaceutical Group.
2m Jan 30
2m
Pharmaceutical Executive Daily: The Disconnect Between Pharma and MedTech
In today’s Pharmaceutical Executive Daily, MJH Life Sciences CEO, Mike Hennessy Jr. examines why pharma and medtech still struggle to deliver truly integrated healthcare solutions, questions emerge around U.S. funding tied to global vaccine policy shifts, and the FDA approves a new treatment option for adults with presbyopia.
2m Jan 29
2m
Pharmaceutical Executive Daily: Eli Lilly Enters $1 Billion Research Collaboration with Seamless Therapeutics
In today’s Pharmaceutical Executive Daily, Insilico Medicine and Qilu Pharmaceuticals launch a $120 million collaboration to advance AI-driven cardiometabolic therapies, Eli Lilly enters a billion-dollar research partnership targeting hearing loss, and industry leaders examine what it takes to bring breakthrough rare disease products to patients.
2m Jan 28
2m
Pharmaceutical Executive Daily: Roche Reports Positive Phase II Study Results for Dual GLP-1/GIP Receptor Agonist
In today’s pharmaceutical executive daily, Roche reports positive Phase II results for a dual GLP-1/GIP receptor agonist, procurement leaders reassess compliance risks tied to unmanaged tail spend, and Boehringer Ingelheim enters a $1 billion collaboration with Simcere to advance bispecific antibody research.
2m Jan 27
2m
Pharmaceutical Executive Daily: Mirum Pharmaceuticals Acquires Bluejay Therapeutics
In todays pharmaceutical executive daily, Mirum Pharmaceuticals strengthens its rare disease portfolio through a $268 million acquisition, industry experts examine why data visualization remains a weak point in biotech decision-making, and pediatricians weigh in on evolving vaccine guidance amid ongoing debate.
2m Jan 26
2m
Pharmaceutical Executive Daily: Tariff Uncertainty Accelerates Manufacturing Shifts
In today’s Pharmaceutical Executive Daily, tariff uncertainty triggers a short-term surge in pharmaceutical manufacturing activity, workforce burnout threatens the stability of the blood supply, and industry leaders assess whether artificial intelligence in pharma is reaching a critical inflection point.
2m Jan 23
2m
Pharmaceutical Executive Daily: United States' Set to Exit WHO
In today’s Pharmaceutical Executive Daily, the World Health Organization finalizes the United States’ withdrawal from the global health body, Bristol Myers Squibb enters an $850 million collaboration with Janux Therapeutics to advance tumor-activated cancer therapies, and industry leaders examine how real-world data is increasingly shaping patient access decisions.
2m Jan 22
2m
Pharmaceutical Executive Daily: New Study Finds No Evidence Linking Tylenol Use to Autism Risk
In today’s Pharmaceutical Executive Daily, a new study reignites debate over a potential link between Tylenol use and autism risk, TopGum signs a $12 million letter of intent to acquire US manufacturing operations, and industry leaders weigh whether to build or buy AI capabilities amid accelerating digital transformation.
2m Jan 21
2m
Pharmaceutical Executive Daily: GSK's $2 Billion Acquisition of RAPT Therapeutics
In today’s Pharmaceutical Executive Daily, GSK moves to strengthen its immunology pipeline with a $2 billion acquisition of RAPT Therapeutics, Atkins launches a new partnership to better understand consumer mindsets around GLP-1 use, and Shionogi agrees to acquire Pfizer’s remaining stake in ViiV Healthcare.
2m Jan 20
2m
Pharmaceutical Executive Daily: Henlius' Exclusive License Agreement with U-Mab Biopharma
In today’s Pharmaceutical Executive Daily, Henlius enters a global exclusive licensing agreement with UMAb Biopharma for a potential best-in-class anti-IL-1RAP antibody, a new report highlights drugmakers raising list prices amid pricing agreements with the Trump administration, and Novartis urges governments to address mounting global trade policy challenges impacting the biopharmaceutical ind...
2m Jan 19
2m
Pharmaceutical Executive Daily: President Trump's Great Healthcare Plan
In today’s Pharmaceutical Executive Daily, Johnson & Johnson announces plans for a second $2 billion manufacturing facility in North Carolina, President Trump calls on Congress to enact a sweeping healthcare reform package, and new analysis highlights how frontline biopharma sales professionals are rethinking compensation and financial planning strategies.
2m Jan 16
2m
Pharmaceutical Executive Daily: Continued Coverage of the 2026 J.P. Morgan Healthcare Conference
In today’s Pharmaceutical Executive Daily we will focus on the 44th Annual J.P. Morgan Healthcare Conference, with Genmab outlining a disciplined strategy focused on sustained growth over the next decade, AbbVie highlighting continued pipeline advancements as it prepares for future revenue transitions, and Novavax detailing its shift toward a partnership-driven operating model.
2m Jan 15
2m
Pharmaceutical Executive Daily: 2026 J.P. Morgan Healthcare Conference Coverage
In today’s Pharmaceutical Executive Daily we will focus on the 44th Annual J.P. Morgan Healthcare Conference, with Biogen outlining how a more focused company is emerging following years of transformation, Merck detailing its strategy to de-risk long-term funding and pipeline investment, and Eli Lilly reinforcing its confidence in sustaining GLP-1-driven growth.
2m Jan 14
2m
Pharmaceutical Executive Daily: Johnson & Johnson Continues $55 Billion Manufacturing Investment
In today’s Pharmaceutical Executive Daily, Johnson & Johnson reaches an agreement with the Trump administration while continuing its $55 billion U.S. investment plan, Bristol Myers Squibb outlines its long-term strategic focus at JPMorgan 2026, and Pfizer details its pivot from COVID-era products toward pipeline execution.
2m Jan 12
2m
Pharmaceutical Executive Daily: FDA Limits Regulations of Non-Medical Fitness Devices
In today’s Pharmaceutical Executive Daily, the FDA moves to limit regulation of non-medical fitness wearables, industry leaders examine how humans and AI can jointly create value in pharma, and Eli Lilly enters a billion-dollar agreement to acquire Ventyx Biosciences.
2m Jan 08
2m
Pharmaceutical Executive Daily: Amgen Acquires Dark Blue Therapeutics for $840 Million
In today’s Pharmaceutical Executive Daily, Amgen announces an $840 million acquisition of Dark Blue Therapeutics, GSK enters a multi-year precision medicine collaboration with Helix, and industry leaders examine how workable operating models are reshaping cell and gene therapy commercialization.
2m Jan 07
2m
Pharmaceutical Executive Daily: Alnylam Invests $250 Million in Manufacturing Facility
In today’s Pharmaceutical Executive Daily, Eli Lilly and Nimbus Therapeutics announce a major licensing deal for oral obesity treatments, Hoth Therapeutics expands its intellectual property portfolio with new provisional patents, and Alnylam commits $250 million to expand manufacturing capabilities in Massachusetts.
2m Jan 06
2m
Pharmaceutical Executive Daily: Wegovy Pill Becomes Available
In today’s Pharmaceutical Executive Daily, the Wegovy Pill becomes the first available oral GLP-1 for weight management, clears a new therapy to prevent motion-induced vomiting, and Sanofi enters a new antibody discovery collaboration targeting autoimmune disease.
2m Jan 05
2m
Pharmaceutical Executive Daily: FDA Approves Wegovy Pill
In today’s Pharmaceutical Executive Daily, the FDA approves Novo Nordisk’s oral Wegovy for chronic weight management, clears Roche’s Lunsumio Velo for adults with relapsed or refractory follicular lymphoma, and Alnylam announces a $250 million investment in a new Massachusetts manufacturing facility.
2m Dec 23, 2025
2m
Pharmaceutical Executive Daily: Nine New Additions to TrumpRx
In today’s Pharmaceutical Executive Daily, President Trump announces nine additional participants in the TrumpRx program, AstraZeneca reaches a $2 billion licensing agreement with Jacobio Pharma for a pan-KRAS inhibitor, and BioMarin enters a definitive $4.8 billion agreement to acquire Amicus Therapeutics.
2m Dec 22, 2025
2m
Scaling Sustainability: A Big Pharma Formula
In this enlightening conversation with Pharm Exec, Jim Greffet, VP of sustainability at Eli Lilly, unpacks how environmental, social, and governance (ESG) goals are shaping the organization's next phase of growth—particularly as demand surges for its GLP-1 products Zepbound and Mounjaro. From access and affordability to supply chain expansion and climate commitments, Greffet discusses the impor...
17m Dec 22, 2025
17m
Pharmaceutical Executive Daily: US Senate Passes Biosecure Act
In today’s Pharmaceutical Executive Daily, Eli Lilly announces positive topline Phase III data for its oral GLP-1 candidate orforglipron, the U.S. Senate passes the Biosecure Act with implications for biopharma supply chains, and industry experts examine how rebate consultants are shaping biosimilar adoption.
2m Dec 19, 2025
2m
Pharmaceutical Executive Daily: Pfizer's Stock Drops Following 2026 Revenue Projections Release
In today’s Pharmaceutical Executive Daily, Pfizer discloses its 2026 revenue expectations, a bipartisan group of House Republicans moves to force a vote on extending ACA tax credits, and new collaboration and merger activity highlights continued dealmaking momentum across biopharma.
2m Dec 18, 2025
2m
Pharmaceutical Executive Daily: FDA's Approval of Lerochol
In today’s Pharmaceutical Executive Daily, the FDA approves a new LDL-lowering therapy, Sanofi announces two strategic deals spanning Alzheimer’s disease and B-cell depletion, and the agency issues a national priority voucher tied to Tecvayli in multiple myeloma.
2m Dec 17, 2025
2m
Pharmaceutical Executive Daily: TrumpRx's Critical Blind Spot
In today’s Pharmaceutical Executive Daily, new analysis highlights access gaps in the TrumpRx framework, the FDA awards a national priority voucher tied to Tecvayli in multiple myeloma, and Sobi announces a $1.5 billion agreement to acquire a gout therapy.
2m Dec 16, 2025
2m
Pharmaceutical Executive Daily: Retatrutide's Positive Phase III Trial Results
In today’s Pharmaceutical Executive Daily, Eli Lilly reports positive topline Phase III results for retatrutide, the FDA expands Amgen’s Uplizna label into generalized myasthenia gravis subtypes, and new analysis explores whether pharmaceutical manufacturing is truly moving back onshore.
2m Dec 15, 2025
2m
Pharmaceutical Executive Daily: FDA's Approval of Waskyra
In today’s Pharmaceutical Executive Daily, new analysis outlines what it may truly cost to fix the biopharma ecosystem, the FDA approves Waskyra for patients with Wiskott-Aldrich syndrome, and OTR Therapeutics enters a strategic collaboration with Zealand to develop novel metabolic disease therapies.
2m Dec 11, 2025
2m